CAMX.ST

Camurus AB

Next est. report 2026-11-05 · BMO

GLP-1 Long '24: Peptide Producers/Designers

Loading…

Overview

Camurus AB develops and commercializes medicines for severe and chronic diseases, leveraging its FluidCrystal technology. Key products include Buvidal for opioi

Camurus AB develops and commercializes medicines for severe and chronic diseases, leveraging its FluidCrystal technology. Key products include Buvidal for opioid dependence and Oczyesa for acromegaly, with strong European growth. Brixadi, for opioid use disorder, generates significant U.S. royalties. The company is advancing pipeline assets like CAM2029 for GEP-NET and CAM2056 for metabolic diseases, supported by strategic partnerships.

What They Do (Plain English & Analogies): Camurus is a pharmaceutical company that creates special, long-lasting medicines for serious and ongoing health problems. Instead of needing to take a pill every day, they develop treatments that can be given as a single injection and work for weeks or even months. They achieve this using their unique "FluidCrystal" technology, which acts like a tiny, smart sponge that holds the medicine and slowly releases it into the body. This approach makes treatment much simpler for patients, as they don't have to remember frequent doses, and it can also improve how effectively the medicine works. Currently, their main products help people with opioid dependence, and they are actively developing new medicines for conditions such as growth hormone disorders, certain cancers, and metabolic diseases like obesity and diabetes.
Very Brief History: Camurus AB was founded in 1991 in Lund, Sweden, by scientists with expertise in biophysical, food, and pharmaceutical chemistry. Initially focused on developing nanoscale drug-delivery systems using lipid phase structures, the company evolved into a science-led biopharmaceutical firm. Over time, it began developing and commercializing its own innovative, long-acting medicines, notably Buvidal for opioid dependence, and has since expanded its pipeline into various severe and chronic diseases.
"Street Stereotype": Camurus is generally perceived as an innovative, science-led biopharmaceutical company, primarily recognized for its proprietary FluidCrystal® drug delivery technology, which enables the creation of long-acting injectable medicines. It is seen as a specialist in improving patient adherence for chronic diseases, particularly in the treatment of opioid dependence, and is increasingly gaining recognition for its potential in endocrine and metabolic disorders through its developing pipeline and strategic partnerships. The market likely views Camurus as a growth-oriented company with a strong R&D focus and a robust financial position, despite recent regulatory setbacks for one of its pipeline products.
Subsidiaries On Linked In*: Camurus Inc — US subsidiary
Camurus GmbH — German subsidiary
Camurus Ltd — UK subsidiary
Camurus Oy — Finnish subsidiary
Camurus AS — Norwegian subsidiary
Camurus SAS — French subsidiary
Camurus Pty Ltd — Australian subsidiary
Camurus S.L — Spanish subsidiary
Camurus ApS — Danish subsidiary
Camurus BV — Dutch subsidiary
Camurus Austria GmbH — Austrian subsidiary
Customer Sectors & Example Clients: Camurus' customers are primarily within the **healthcare sector**. This includes: hospitals and clinics, healthcare providers and physicians who prescribe and administer their medications, correctional facilities (for opioid use disorder treatment), and pharmacies (involved in distribution and sometimes administration). They also interact with governments and public health systems through national funding and reimbursement schemes. While Camurus sells to healthcare systems and providers rather than directly to large corporate clients, their strategic partners include: * **Braeburn Pharmaceuticals:** Commercializes Brixadi in the U.S. * **Eli Lilly and Company:** Collaborates on long-acting incretin products for cardiometabolic health. * **Gubra A/S:** Collaborates on a long-acting parathyroid hormone analog program. * **Rhythm Pharmaceuticals Inc.:** (from existing text tables) Partner for CAM4072 for genetic obesity disorders.
New Customers / Segments They'Re Targeting: Camurus is actively targeting new patient populations and therapeutic areas through its pipeline development and commercial expansion. Key new segments include: * **Gastroenteropancreatic neuroendocrine tumors (GEP-NET):** With CAM2029, currently in the SORENTO study. * **Polycystic liver disease (PLD):** Also with CAM2029, following positive Phase II results. * **Metabolic diseases (e.g., obesity, diabetes):** Through its CAM2056 program (a once-monthly semaglutide depot) and an expanded collaboration with Eli Lilly for amylin receptor agonists and dual/triple incretin agonists. * **Acromegaly patients in the U.S.:** With the planned launch of Oclaiz (the U.S. name for CAM2029/Oczyesa) following regulatory resubmission. * **Patients transitioning from competitor products:** Specifically, patients in Australia previously on Indivior's Sublocade, which is being withdrawn from the market, are a target for Buvidal.
Supply Chain And Sourcing Geographies: Camurus' supply chain involves the manufacturing of its drug products. The company currently relies on a "third-party site" for manufacturing, which has been subject to FDA inspections. A Complete Response Letter (CRL) for Oclaiz (CAM2029) in the U.S. was issued due to observations during a previous GMP manufacturing inspection at this third-party site. Camurus is strategically working to diversify its manufacturing capabilities by "setting up a second manufacturer," with explicit mention of a "contract manufacturer you are setting in the U.S. right now" in the Q&A, indicating a move to establish a manufacturing presence in the United States. * **Current Primary Manufacturing:** Europe (implied, as the existing manufacturer has regulatory discussions with "other authorities" and the context of European launches suggests European manufacturing). * **Planned/Developing Manufacturing:** United States (for a second manufacturer, specifically in the context of the Oclaiz CRL and U.S. market entry).
Sales Geographies And Expansion Plans: Camurus currently sells its products in: * **Europe:** Including the Nordics, Germany, Spain, France, Sweden, and the U.K. (where sales are improving with new NHS funding). Oczyesa is currently launching in "first-wave European markets" and is available in Sweden, with formulary processes progressing in the U.K. * **Australia:** Buvidal is a leading product in the long-acting injectable buprenorphine segment. * **United States:** Through royalty revenue from Brixadi, which is commercialized by Braeburn Pharmaceuticals. Expansion plans include: * **Broadening Oczyesa adoption** in existing European markets and extending its rollout beyond Germany (e.g., U.K.). * **Launching Oclaiz in the U.S.** for acromegaly, pending FDA resubmission and approval. * **Preparing for CAM2029 in GEP-NET** in the U.S. and Europe. * **Expanding commercial activities**, particularly for the U.S. team, to support upcoming launches.
How Key Themes May Help/Hurt: The "GLP-1 Long '24: Peptide Producers/Designers" theme is bullish, and Camurus is well-positioned to benefit significantly from it. Camurus' proprietary FluidCrystal® technology is highly relevant for the development of long-acting peptide-based drugs, which are central to the GLP-1 market. Their CAM2056 program, a once-monthly semaglutide depot (semaglutide is a GLP-1 receptor agonist), directly targets this growing market for metabolic diseases like obesity and diabetes. The expanded collaboration with Eli Lilly, a leader in metabolic diseases, to include amylin receptor agonists and dual/triple incretin agonists further validates their technology and provides access to Lilly's expertise and commercial reach in this high-demand area. The rising global prevalence of obesity (Bull1 from theme context) directly increases the market size for GLP-1 drugs, which Camurus is actively pursuing. Their technology's ability to improve adherence for chronic conditions (Bull3 from theme context, strategic partnerships) is a key advantage in the long-acting GLP-1 space. While the theme is generally bullish, the intensifying competitive landscape (Bear1 from theme context) could pose a challenge. The GLP-1 market is highly competitive with major pharmaceutical players. Camurus, while having a strong technology, will need to differentiate CAM2056 effectively against existing and emerging weekly/daily GLP-1s and other long-acting formulations. Regulatory hurdles (Bear2 from theme context) could also impact their GLP-1 pipeline, similar to the recent CRL for Oclaiz, though the specific issues for Oclaiz were manufacturing-related.

3 Main Long-Term Bull Details

Proprietary FluidCrystal® Technology: This versatile and validated drug delivery platform enables the development of long-acting injectables across various therapeutic areas, offering improved patient adherence and convenience, which are critical for chronic diseases. This technology underpins both their commercial products and a rich pipeline, providing a sustainable competitive advantage.
Diversified and Promising Pipeline: Beyond established products for opioid dependence, Camurus has a pipeline targeting significant unmet needs in areas like acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), polycystic liver disease, and metabolic diseases (e.g., CAM2029, CAM2056). The SORENTO readout for CAM2029 in GEP-NET is a major near-term catalyst, and the GLP-1 related programs (CAM2056, Lilly collaboration) tap into a rapidly expanding market.
Strong Financial Position and Strategic Partnerships: The company is sustainably profitable, debt-free, and holds a substantial cash position (SEK 4.1 billion as of Q2 2026), providing flexibility for organic growth, pipeline development, and potential business development opportunities. Collaborations with major players like Eli Lilly and Braeburn Pharmaceuticals validate their technology and extend their market reach and development capabilities.

3 Main Long-Term Bear Details

Regulatory Risks and Manufacturing Reliance: The recent Complete Response Letter (CRL) from the FDA for Oclaiz in the U.S. due to manufacturing inspection observations highlights ongoing regulatory hurdles and potential reliance on third-party manufacturers. While they are setting up a second manufacturer, delays in approvals can significantly impact market entry and revenue generation.
Intensifying Competition: In key therapeutic areas like opioid dependence and the emerging metabolic disease space (GLP-1s), Camurus faces strong competition from established pharmaceutical companies with significant resources and market presence. Maintaining market share and achieving significant penetration with new products will require sustained commercial execution and differentiation.
Market Penetration and Capacity Constraints: While Buvidal is a leader in Australia, the transcript mentions "prescribing capacity in parts of the market a limiting factor" and the need to address this with clinics and providers. Expanding market share, even with a competitor withdrawal, still requires overcoming practical challenges in healthcare systems and ensuring adequate treatment infrastructure.

Competitors And Differentiation: In the opioid dependence market, a key competitor mentioned is **Indivior**, whose product **Sublocade** is being withdrawn from the Australian market. Other competitors in the broader opioid use disorder market include Alkermes (Vivitrol), Orexo (Zubsolv), and Collegium Pharmaceutical. Camurus differentiates itself through its **proprietary FluidCrystal® technology**. This technology enables the development of long-acting injectable medicines that provide sustained drug release over extended periods (from days to months) with a single subcutaneous injection. This offers several competitive advantages: * **Improved patient adherence:** Reduces the burden of frequent dosing and can allow for self-administration, which is crucial for chronic conditions. * **Consistent medication levels:** Leads to more stable therapeutic effects and potentially better treatment outcomes. * **User-friendly administration:** Designed for pre-filled syringes or auto-injector pens, simplifying the process for patients and healthcare professionals. * **Versatility:** The technology can be combined with various active pharmaceutical ingredients, including small molecules, peptides, and proteins, allowing for a broad pipeline across different therapeutic areas.
Recent Performance & What The Market'S Focused On: Camurus reported a solid second quarter of 2026, marking a clear return to growth. Total revenues were SEK 702 million, up 4% year-on-year and 32% sequentially. Product sales reached a record SEK 528 million, the first time exceeding SEK 0.5 billion in a quarter. Buvidal sales grew 12% year-on-year and 24% sequentially, and Brixadi royalties in the U.S. increased 42% year-on-year. The operating result was SEK 293 million (42% margin), and the company ended the quarter with SEK 4.1 billion in cash, remaining debt-free. The market is currently focused on: * **Resolution of the Oclaiz (acromegaly) U.S. regulatory pathway:** Following the Complete Response Letter from the FDA, the market is awaiting the resubmission confirmation and a new PDUFA target action date. * **SORENTO study readout in GEP-NET:** This is a major pipeline catalyst expected in Q4 2026, with a positive outcome potentially opening a significant new growth avenue for CAM2029. * **Progress of the metabolic disease pipeline:** The start of CAM2056 Phase II-B and the expanded collaboration with Eli Lilly for amylin receptor agonists are key indicators of future growth in the GLP-1 and incretin space. * **Commercial execution of Oczyesa in Europe:** Broadening adoption and market share in acromegaly. * **Integration of patients from Sublocade withdrawal in Australia:** How effectively Camurus can capture the market share left by the competitor.

Revenue Segments And Estimated Mix: Product Sales — Mix: ~75.2%; Source: Q2 2026 transcript; Trend: Up 13% year-on-year and 24% sequentially, marking a record quarter.
Brixadi Royalties (U.S.) — Mix: ~18.1%; Source: Q2 2026 transcript; Trend: Increased 42% year-on-year and 20% sequentially, a record royalty quarter.
Milestone Payments — Mix: ~6.6%; Source: Q2 2026 transcript; Trend: SEK 46 million in Q2 2026, down from SEK 150 million in Q2 2025.
Product Brands: Buvidal
Brixadi
Oczyesa
Oclaiz
CAM2029
CAM2056
CAM2038
CAM2043
CAM2032
CAM4072
CAM4071
CAM2047
FluidCrystal

Bull / Bear Details

Camurus demonstrates a compelling bullish investment case as of 2026-07-16, driven by robust commercial execution of its long-acting therapies Buvidal and Brixa

Thesis

Camurus demonstrates a compelling bullish investment case as of 2026-07-16, driven by robust commercial execution of its long-acting therapies Buvidal and Brixadi, and a strong pipeline with multiple near-term catalysts. Despite a U.S. regulatory setback for Oclaiz, the issue is manufacturing-related and remediated, with a resubmission expected. The company's financial strength and strategic partnerships further underpin its growth potential, particularly in the expanding GLP-1 and opioid dependence markets.

Bull case

Camurus exhibits strong commercial momentum with record product sales and significant growth across its key assets. Buvidal sales grew 12% year-on-year, and Brixadi royalties in the U.S. surged by 42% year-on-year, benefiting from an expanding U.S. long-acting injectable market for opioid dependence. The Oczyesa launch in Europe is progressing well, aiming for double-digit market share in acromegaly.
The company's pipeline is rich with near-term catalysts, offering substantial future growth potential. The SORENTO study for CAM2029 in GEP-NET is expected to deliver primary results in Q4 2026, potentially establishing it as a new first-line treatment. Additionally, the CAM2056 Phase II-B trial for a once-monthly semaglutide depot is on track to start in H2 2026, addressing a meaningful opportunity in metabolic diseases.
Camurus maintains a strong financial position and benefits from strategic partnerships that validate its FluidCrystal technology. The company is debt-free with SEK 4.1 billion in cash, providing flexibility for organic growth and business development. Eli Lilly expanded its collaboration to include amylin receptor agonists, further validating Camurus' long-acting metabolic medicine platform.

Bear case

Regulatory hurdles and delays, particularly the U.S. Complete Response Letter (CRL) for Oclaiz (CAM2029) in acromegaly, introduce uncertainty. While the CRL was manufacturing-related and remediations are complete, an FDA inspection is highly likely, potentially delaying U.S. market entry beyond initial expectations and impacting revenue timelines.
Despite strong market positions, competitive pressures and market penetration challenges persist. While Buvidal is a leader in Australia, prescribing capacity remains a limiting factor. Brixadi, though growing, holds about 30% of equivalent units in the U.S. long-acting injectable segment, indicating significant competition and the need for sustained investment to capture further market share.
The success of pipeline assets, especially the critical SORENTO readout for CAM2029 in GEP-NET, carries inherent execution risk. A negative or inconclusive outcome from this study would significantly impact the company's near-term growth trajectory and valuation, as CAM2029 is considered a central near-term value driver.

Bull / Bear Case

Bear Case: Despite strong Q2 results, Camurus faces significant risks. Regulatory hurdles persist, notably the U.S. Complete Response Letter for Oclaiz (CAM2029) in acromegaly, which, though manufacturing-related, necessitates a likely FDA inspection and could delay U.S. market entry beyond expectations. This introduces uncertainty into revenue timelines. Competitive pressures and market penetration challenges are evident, with prescribing capacity limiting Buvidal's growth in Australia and Brixadi holding only about 30% of equivalent units in the competitive U.S. market. Furthermore, the success of critical pipeline assets like CAM2029 in GEP-NET (SORENTO readout) carries inherent execution risk; a negative outcome would significantly impact the company's near-term growth trajectory and valuation. The stock's recent underperformance and "Falling Star" classification also suggest underlying market skepticism.
Bull Case: Camurus demonstrates strong commercial momentum with record Q2 2026 product sales of SEK 528 million, marking a clear return to growth. Buvidal sales increased 12% year-on-year, and Brixadi royalties in the U.S. surged by 42% year-on-year, benefiting from a rapidly expanding U.S. long-acting injectable market for opioid dependence. The Oczyesa launch in Europe is progressing well, aiming for double-digit market share in acromegaly. The pipeline is rich with near-term catalysts, including the anticipated Q4 2026 SORENTO study readout for CAM2029 in GEP-NET, which could establish it as a new first-line treatment, and the CAM2056 Phase II-B trial for a once-monthly semaglutide depot starting in H2 2026. The company maintains a robust financial position, being debt-free with SEK 4.1 billion in cash, and its FluidCrystal technology is further validated by an expanded collaboration with Eli Lilly.
More Compelling & Why: Bear. While Q2 results were strong and the stock jumped post-earnings, the current EV/EBITDA of approximately 35.23 is elevated for a company classified as a "Falling Star" with recent underperformance. This valuation appears to heavily discount future pipeline success, particularly for the critical SORENTO readout and Oclaiz U.S. approval, which still carry execution and regulatory risks. My view would flip to Bull if the EV/EBITDA multiple compressed to below 25x, or if both SORENTO delivers unequivocally positive results and Oclaiz secures U.S. approval without further substantial delays.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
U.S. FDA Approval of Oclaiz (CAM2029) for Acromegaly	U.S. market entry for Oclaiz represents a significant commercial opportunity, expanding beyond European launches and validating the CAM2029 platform, despite the Complete Response Letter (CRL) received in June 2026.	Confirmation of NDA resubmission, a new PDUFA target action date, and the final FDA decision. An FDA inspection of the third-party manufacturer is highly likely.	FDA approval = bullish signal. Further delays (e.g., beyond early 2027), another CRL, or rejection = bearish signal.	Company press releases, FDA announcements, regulatory news services. Resubmission confirmation expected in the near term, with 2026 being an opportunity.	FDA website for drug approvals (e.g., Drugs@FDA), industry news sites (e.g., BioWorld, FierceBiotech).	IQVIA: Prescription data for acromegaly treatments in the U.S.
Buvidal Market Share Capture and Sales Growth in Australia	The withdrawal of a competitor's long-acting buprenorphine product by the end of 2026 presents a significant opportunity for Buvidal to increase its already dominant market share (over 80% of the LAIB segment) in Australia, driving revenue growth.	Q4 2026 and Q1 2027 Buvidal sales figures for Australia, patient transfer rates, and updates on addressing prescribing capacity constraints.	Rapid and substantial transfer of patients (e.g., 'vast majority' as seen in Europe) to Buvidal, leading to accelerated sales growth (e.g., >20% sequential growth) in Australia in Q1 2027 = bullish signal. Slower than expected patient transfers or persistent capacity issues limiting growth = bearish signal.	Company quarterly reports, earnings calls.	Industry reports on opioid dependence treatment in Australia, news articles on market dynamics.	IQVIA: Prescription data for long-acting buprenorphine products in Australia.
SORENTO Phase III Study Primary Results Readout for CAM2029 in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)	This is Camurus' most important pipeline catalyst for 2026, with a positive outcome potentially establishing CAM2029 as a new first-line treatment option in a substantial and growing market, opening a very meaningful new growth avenue for the company.	Announcement of primary results after reaching the target of 194 progression-free survival events.	Positive outcome, demonstrating statistically significant improvement in progression-free survival, supporting CAM2029 as a new first-line treatment option = bullish signal. Negative or inconclusive outcome, failing to meet primary endpoints or show significant benefit = bearish signal.	Company press releases, investor presentations, regulatory filings (if applicable), medical conferences. Expected in Q4 2026.	ClinicalTrials.gov: Status updates for NCT05050942 (SORENTO study).	EvaluatePharma: Consensus sales forecasts for CAM2029 post-approval.
Initiation of CAM2056 Phase II-B Clinical Trial (Once-Monthly Semaglutide Depot)	This trial is a crucial step in developing a long-acting GLP-1 agonist, aligning with the bullish thesis for peptide producers and addressing adherence challenges in a large metabolic disease market.	Company announcement regarding the start of patient enrollment for the Phase II-B trial, including details on trial design, size, duration, and dose levels.	Trial initiation on schedule (H2 2026) = bullish signal, indicating pipeline progression. Significant delays in trial initiation beyond H2 2026 or cancellation = bearish signal.	Company press releases, investor presentations, clinical trial registries (e.g., ClinicalTrials.gov). Expected in H2 2026.	ClinicalTrials.gov: Status updates for CAM2056 trial.	GlobalData: Clinical trial intelligence for metabolic disease drugs.
Brixadi Royalty Revenue Growth in the U.S.	Brixadi royalties are a significant and re-accelerating revenue stream for Camurus, reflecting strong underlying demand and market expansion in the U.S. opioid use disorder segment, which is estimated at $1.2 billion annually and growing over 30% year-on-year.	Quarterly Brixadi royalty revenue figures, year-on-year and sequential growth rates. Management commentary on partner Braeburn's commercial investments and market share (currently estimated at 30% of equivalent units).	Sustained year-on-year royalty revenue growth above 30% and positive sequential growth in Q3 and Q4 2026 = bullish signal. Significant deceleration in growth (e.g., below 20% YoY) or sequential decline in royalties = bearish signal.	Company quarterly reports, earnings calls.	Braeburn Pharmaceuticals press releases (if they provide sales updates), industry reports on the U.S. opioid use disorder market.	Symphony Health Solutions: U.S. prescription data for Brixadi.

Key Reported Metrics, Reratings Triggers & Results3 rows

Represents a rapidly growing revenue stream in a large, expanding U.S. market for opioid dependence. Continued strong growth validates the U.S. strategy and par

Key reported metrics
Metric	Last period	Why it matters
Brixadi Royalties (U.S.)	42%	Represents a rapidly growing revenue stream in a large, expanding U.S. market for opioid dependence. Continued strong growth validates the U.S. strategy and partnership with Braeburn.
SORENTO Readout for CAM2029 in GEP-NET	N/A	This is a critical pipeline catalyst expected in Q4 2026. A positive outcome could establish CAM2029 as a new first-line treatment, opening a significant new growth avenue for Camurus.
Total Revenues	4%	Indicates overall company performance and growth trajectory, especially after a 'softer start' to the year. Investors will watch for sustained momentum and a continued return to growth.

Key Questions

Will the SORENTO Phase III trial for CAM2029 in GEP-NET deliver positive primary results in Q4 2026, validating a significant new growth avenue for Camurus?

Question 2: Will Camurus successfully resubmit the Oclaiz NDA and secure U.S. FDA approval for acromegaly in 2026 or early 2027, resolving the manufacturing-related Complete Response Letter?
Question 3: Can Buvidal sustain its strong growth, particularly by effectively capturing market share in Australia following the competitor withdrawal, and will Brixadi royalties continue their accelerated growth in the expanding U.S. market?

Earnings Transcript SummaryTable

2026-07-15 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Commercial execution: Extending leadership in opioid dependence with Buvidal and Brixadi, advancing the Oczyesa launch in Europe, and strengthening readiness for broader CAM2029 commercial efforts. 2. Advancing the pipeline: Progressing multiple near-term catalysts including the SORENTO readout in GEP-NET, the start of CAM2056 phase II-B, and the U.S. resubmission pathway for Oclaiz. 3. Maintaining financial strength: Ensuring a strong and flexible balance sheet to finance organic growth, commercial expansion, and pipeline development, while evaluating partnerships and business opportunities.	The overall takeaway of the call was positive and confident. Camurus delivered a strong second quarter, marking a clear return to growth after a softer start to the year, with record product sales and robust year-on-year growth for Buvidal and Brixadi. The company is actively advancing its pipeline with several significant catalysts expected in the second half of 2026, including the SORENTO readout and CAM2056 Phase II-B study. Despite the U.S. Complete Response Letter for Oclaiz, management expressed confidence in addressing the manufacturing-related issues and reiterated full-year guidance. The tone was optimistic, emphasizing disciplined investment and a strong financial position to support future growth and strategic opportunities.	In Q1 2026, total revenues decreased 5% year-on-year. Product sales decreased 12% year-on-year. Reported Buvidal sales were down 13% year-on-year. Brixadi royalties increased 44% year-on-year. Oczyesa generated SEK 4 million in sales, marking its first full commercial quarter.	1. Buvidal growth drivers and Q3 expectations: Analysts questioned if Q2 growth was due to stocking and the potential impact of the Q3 holiday season in Europe. Management responded that the growth was driven by underlying demand with no one-off effects, and while Q3 can be affected by holidays, past Q3 developments have been 'relatively okay,' but it's too early to give specific predictions. 2. Oclaiz CRL and U.S. approval timeline/manufacturer inspection: Analysts sought clarification on the status of the U.S. Complete Response Letter (CRL), reasons for not moving to a U.S. manufacturing line, and the likelihood of an FDA inspection. Management stated that remediations for the CRL (related to a third-party GMP manufacturing inspection and an oxygen scavenger point) have been completed, and they are hopeful for a resubmission confirmation soon, with 2026 being an opportunity. They emphasized the strategic need for broader manufacturing capabilities and that an FDA inspection is 'highly likely.' 3. Australia market dynamics: Analysts inquired about the impact of a competitor's withdrawal on Buvidal's market share and the potential for the overall long-acting market to reach 50% penetration, given current capacity constraints. Management expects a 'vast majority' of patients from the withdrawn product to transfer to Buvidal 'shortly after the supply is out in end of 2026,' based on previous transitions. They acknowledged capacity issues but are addressing them with initiatives like pharmacy injection programs and noted the increasing flux of patients from methadone to buprenorphine as a future growth source.	Total revenues were SEK 702 million, up 4% year-on-year. Product sales reached a record of SEK 528 million, up 13% year-on-year. Buvidal grew 12% year-on-year. Brixadi royalties in the U.S. increased 42% year-on-year. Oczyesa generated SEK 4 million in sales in its first-wave European markets.

Transcript TidbitsTable

2026-07-15

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
The U.S. long injectable segment for opioid dependence is estimated to be around $1.2 billion on an annualized basis and growing more than 30% year-on-year, yet it still represents only about 10% of the roughly 2 million patients treated, leaving substantial room for conversion to long-acting therapy. CAM2029 is a broad opportunity across acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease, with GEP-NET being a substantial and growing market with considerable unmet medical needs. A positive outcome for CAM2029 in GEP-NET would support it as a new first-line treatment option, opening a very meaningful new growth avenue for Camurus. Oczyesa's launch in Germany aims for broadening adoption and moving towards a double-digit share of acromegaly patients. In Australia, Buvidal holds over 30% of the overall market share, with a potential to reach 50%, and there's an increasing flux of patients from methadone to buprenorphine. CAM2056, a once-monthly semaglutide depot, addresses a meaningful opportunity for once-monthly incretin therapies given adherence challenges with current weekly and daily treatments. Lilly expanded its collaboration to include amylin receptor agonists, broadening the scope in the long-acting metabolic medicine space.	Buvidal remains the clear leader in Australia with over 80% of the long-acting injectable buprenorphine (LAIB) segment. Another long-acting buprenorphine product, which holds a minority share of the LAIB segment in Australia, is being withdrawn from the market by the end of 2026. Camurus' priority is to ensure continuity of care for patients, expecting most to transfer to Buvidal, similar to previous transitions in Sweden, Finland, and Germany. Brixadi holds about 30% of equivalent units in the U.S. long injectable segment.	The U.S. long injectable segment for opioid dependence is a growing market, estimated at $1.2 billion annually and expanding over 30% year-on-year. There is a recognized challenge with adherence for current weekly and daily incretin treatments, highlighting the need for once-monthly therapies. In Australia, there's an increasing trend of patients transitioning from methadone to buprenorphine for opioid dependence treatment.	Camurus is on track towards its ambition of 100,000 Buvidal patients by the end of 2027. The SORENTO study for CAM2029 in GEP-NET is expected to reach its target of 194 progression-free survival events in the fourth quarter of 2026, followed by the readout of primary results, which could establish CAM2029 as a new first-line treatment option. The U.S. resubmission pathway for Oclaiz is a near-term catalyst, with 2026 being an opportunity for resubmission confirmation. The CAM2056 phase II-B clinical trial is on track to start in the second half of 2026, with ongoing product design work for an auto-injector pen. The company's strategy focuses on commercial execution, pipeline advancement, partnerships and business development, and maintaining financial strength, entering a 'catalyst-rich second half' with strong momentum.	Peptide	The increasing demand for long-acting therapies across various chronic conditions (e.g., opioid dependence, metabolic diseases, neuroendocrine tumors) due to improved adherence and patient convenience. Strategic partnerships and collaborations are crucial for advancing pipeline development and expanding market reach within the biopharmaceutical industry.	I am very pleased to report a solid second quarter, marking a clear return to growth after a softer start of the year for Camurus. Total revenues were SEK 702 million, up 4% year-on-year and 32% sequentially. Commercially, product sales reached a record of SEK 528 million. The financial figures clearly demonstrate strength, which is encouraging. The core margin is clearly improving. Importantly, we remain debt-free, which gives us real flexibility as we look ahead. Buvidal delivered a record quarter with net sales of SEK 524 million. The U.S. long injectable segment is now estimated to be around $1.2 billion on an annualized basis and growing more than 30% year-on-year. We see substantial further growth potential for Brixadi in the U.S. Lilly expanded our collaboration by exercising its option to include amylin receptor agonists. The second quarter showed our model is working with record product sales, strong profitability, disciplined investment, and a robust balance sheet. We now enter a catalyst-rich second half with clear priorities, commercial execution, pipeline advancement, and selective capital deployment.	We received Complete Response Letter for the acromegaly NDA in the U.S. in June. Unfortunately, we have this CRL, that's something we are accounting for. Q3 tends to not be the best quarter for Buvidal in Europe due to the holiday season. Australia was steady, with prescribing capacity in parts of the market a limiting factor that we're addressing with clinics and providers. It's highly likely that there will be an inspection of the manufacturer.	Marketing and distribution expenses rose, reflecting expanding commercial operations and sales growth. An additional SEK 200 million is allocated to expand commercial activities, particularly for the U.S. team, to support the upcoming Oclaiz launch and prepare for CAM2029 in GEP-NET. Braeburn has made significant investment in its U.S. organization, expanding both the commercial field force and medical affairs. Half of the increase in SG&A came from the U.S., with upfront investments depending on potential approval and when the sales force will be hired.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-07-15	Camurus reported a strong Q2 2026, marking a clear return to growth with record product sales and robust Buvidal/Brixadi performance. Despite a U.S. Oclaiz CRL (manufacturing-related, remediated, resubmission expected 2026), pipeline catalysts like SORENTO (Q4 2026 readout) and CAM2056 (H2 2026 start) progressed. The market reacted very positively, with the stock up 21.60% (t+2 days), indicating strong confidence in the company's growth trajectory and ability to overcome regulatory hurdles.	Earnings Transcript	Positive		+21.60% (vs SPY: +21.75%)

Upcoming EventsTable

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
CAMX.ST_22ed0c4d	in the fourth quarter, followed by the readout of primary results	2026-10-01	2026-12-31	Readout of primary results from the SORENTO Phase III study for CAM2029 in gastroenteropancreatic neuroendocrine tumors (GEP-NET).	A positive outcome would support CAM2029 as a new first-line treatment option, opening a meaningful new growth avenue for Camurus.	Ticker	2026-07-15	earnings_transcript